Pfizer

Pharmalot

Pfizer stops developing a cholesterol drug. So who is the big winner?

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Is the 21st Century Cures bill in doubt over drug prices?

By Ed Silverman

Pharmalot

Pfizer fined again for violating environmental law at Puerto Rico plant

By Ed Silverman

Pharmalot

Interfaith investor coalition pushes shareholder resolutions on drug prices

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Chicago plans to require licenses for sales reps who market opioids

By Ed Silverman

Pharmalot

Are concerns about a price war between Johnson & Johnson and Pfizer ‘overblown’?

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Doctors Without Borders chastises Pfizer for refusing to lower vaccine price

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: To avoid scandal, Novartis CEO advises companies not to hire rulebreakers

By Ed Silverman

Pharmalot

Pfizer won’t split into two companies, so what’s next?

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Pfizer decides not to split into two companies

By Ed Silverman

Pharmalot

FDA panel votes to remove serious warning from Pfizer’s smoking cessation pill

By Ed Silverman

Pharmalot

FDA reviewers question Pfizer study about safety of its Chantix smoking cessation pill

By Ed Silverman

Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Pfizer CEO says Clinton drug pricing plan is ‘very negative’

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Are concerns about spending on orphan drugs overblown?

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Docs disciplined for misconduct still paid by pharma to be speakers, advisers

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: India wants you to know its drugs are safe and effective

By Ed Silverman

Business

Pfizer buying Medivation in deal valued at about $14 billion

By Associated Press

Pharmalot

Pharmalot, Pharmalittle: Pfizer pays $14 billion for Medivation and its prostate cancer drug

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: North Korea’s Neo-Viagra has the same ingredient as the real thing

By Ed Silverman

Pharmalot

Pfizer closes plant in India after several regulators find problems

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Bristol-Myers cancer drug misses main goal in late-stage study

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Brexit, schmexit. Glaxo invests $360 million in the UK

By Ed Silverman

Pfizer sues Texas agency over releasing Medicaid data to lawmakers

After a long battle, Pfizer drops the price of its Prevnar vaccine to humanitarian groups

Pharmalot, Pharmalittle: Pfizer may sell or spin off its consumer business

Up and down the ladder: The latest comings and goings

Pfizer stops developing a cholesterol drug. So who is the big winner?

Pharmalot, Pharmalittle: Is the 21st Century Cures bill in doubt over drug prices?

Pfizer fined again for violating environmental law at Puerto Rico plant

Interfaith investor coalition pushes shareholder resolutions on drug prices

Pharmalot, Pharmalittle: Chicago plans to require licenses for sales reps who market opioids

Are concerns about a price war between Johnson & Johnson and Pfizer ‘overblown’?

Pharmalot, Pharmalittle: Pfizer will sell a biosimilar version of Remicade next month

Up and down the ladder: The latest comings and goings

Doctors Without Borders chastises Pfizer for refusing to lower vaccine price

Pharmalot, Pharmalittle: To avoid scandal, Novartis CEO advises companies not to hire rulebreakers

Pfizer won’t split into two companies, so what’s next?

Pharmalot, Pharmalittle: Pfizer decides not to split into two companies

FDA panel votes to remove serious warning from Pfizer’s smoking cessation pill

FDA reviewers question Pfizer study about safety of its Chantix smoking cessation pill

Up and down the ladder: The latest comings and goings

Pharmalot, Pharmalittle: Pfizer CEO says Clinton drug pricing plan is ‘very negative’

Pharmalot, Pharmalittle: Are concerns about spending on orphan drugs overblown?

Pharmalot, Pharmalittle: Docs disciplined for misconduct still paid by pharma to be speakers, advisers

Pharmalot, Pharmalittle: India wants you to know its drugs are safe and effective

Pfizer buying Medivation in deal valued at about $14 billion

Pharmalot, Pharmalittle: Pfizer pays $14 billion for Medivation and its prostate cancer drug

Pharmalot, Pharmalittle: North Korea’s Neo-Viagra has the same ingredient as the real thing

Pfizer closes plant in India after several regulators find problems

Pharmalot, Pharmalittle: Bristol-Myers cancer drug misses main goal in late-stage study

Pharmalot, Pharmalittle: Brexit, schmexit. Glaxo invests $360 million in the UK

Pfizer

Sign up for our Daily Recap newsletter